Resolving a double standard for risk management of Thalidomide: An evaluation of two different risk management programmes in Japan

Drug Safety

Volumn 33, Issue 1, 2010, Pages 35-45

  Ooba, Nobuhiro ^a   Sato, Tsugumichi ^a,b   Watanabe, Hikaru ^a,b   Kubota, Kiyoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Drug Safety Research Laboratory   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ARTICLE; BEHCET DISEASE; COLON CANCER; CONTROLLED STUDY; CROHN DISEASE; DRUG INFORMATION; DRUG MANUFACTURE; DRUG MONITORING; DRUG SAFETY; FEMALE; GRAFT VERSUS HOST REACTION; HEALTH PROGRAM; HEALTH SERVICES RESEARCH; HUMAN; INFORMATION RETRIEVAL; JAPAN; KIDNEY CARCINOMA; LEPROSY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; OFF LABEL DRUG USE; PATIENT EDUCATION; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK MANAGEMENT; SOLID TUMOR; STANDARDIZATION;

COMMERCE; DRUG APPROVAL; HUMANS; JAPAN; LEGISLATION, DRUG; MULTIPLE MYELOMA; OFF-LABEL USE; PHYSICIANS; PRESCRIPTION DRUGS; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY ASSURANCE, HEALTH CARE; RECORDS AS TOPIC; RISK MANAGEMENT; THALIDOMIDE;

EID: 72049120368     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11318920-000000000-00000     Document Type: Article

References (38)

1. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6: 303-306
2. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571
3. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991-995
4. Terpos E, Mihou D, Szydlo R, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005; 19: 1969-1976
5. Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2005; 132: 584-593
6. Gracia-Sanz R. Thalidomide in multiple myeloma. Expert Opin Pharmacother 2006; 7: 195-213
7. Anagnostopoulos A, Wever D, Rankin K, et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121: 768-771
8. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825-831
9. Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dex-amethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008; 26: 2171-2177
10. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370: 1209-1218
11. Marriott JB, Muller G, Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunol Today 1999; 20: 538-540
12. Adlard JW. Thalidomide in the treatment of cancer. Anti-cancer Drugs 2000; 11: 787-791
13. Stirling D. Thalidomide: a novel template for anticancer drugs. Semin Oncol 2001; 28: 602-606
14. Raje N, Anderson K. Thalidomide and immunomodulatory drugs as cancer therapy. Curr Opin Oncol 2002; 14: 635-640
15. Ng SSW, Brown M, Figg WD. Thalidomide, an anti-angiogenic agent with clinical activity in cancer. Biomed Pharmacother 2002; 56: 194-199
16. Tim E. Thalidomide in solid malignancies. J Clin Oncol 2002; 20: 2607-2609
17. Singhal S, Mehta J. Thalidomide in cancer. Biomed Pharmacother 2002; 56: 4-12
18. Baidas SM, Winer EP, Fleming GF, et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000; 18: 2710-2717
19. Lago LD, Richter MF, Cancela AI, et al. Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. Invest New Drug 2003; 21: 359-366
20. Motzer RJ, Berg W, Ginsberg M, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002; 20: 302-306
21. Escudier B, Lassau N, Counanet D, et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002; 13: 1029-1035
22. Tseng JE, Glisson BS, Khuri F, et al. Phase II study of the antiangiogenesis agent thalidomide in recurrent or meta-static squamous cell carcinoma of the head and neck. Cancer 2001; 92: 2364-2373 (Pubitemid 33029081)
23. Schwartz JD, Sung M, Schwartz M, et al. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-a2a upon progression. Oncologist 2005; 10: 718-727
24. Chang SM, Lamborn KR, Malec M, et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma mutiforme. Int J Radiat Oncol Biol Phys 2004; 60: 353-357
25. Gordon JN, Trebble TM, Ellis RD, et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005; 54: 540-545
26. Frank ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004; 363: 1802-1811
27. Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Dis-cov Today 2005; 10: 107-114
28. Bruera E, Neumann CM, Pituskin E, et al. Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncol 1999; 10: 857-859
29. Dearner P. Thalidomide for distressing night sweats in advanced malignant disease. Palliat Med 1998; 12: 208-209
30. Tsuji K, Tsutani K. Personal imports of drugs to Japan in 2005: an analysis of import certificates. J Clin Pharm Ther 2008; 33: 545-552
31. Japanese Society of Hematology. Guidelines for the appropriate use of thalidomide for MM [in Japanese; online]. Available from URL: http://www.jshem.or.jp/info/guideline.html [Accessed 2009 Oct 23]
32. SMUD. SMUD information pages [in Japanese; online]. Available from URL: http://square.umin.ac.jp/pe/smud/smud.htm [Accessed 2009 Jul 15]
33. MHLW. Imported thalidomide by the fiscal year [in Japanese; online]. Available from URL: http://www.mhlw.go.jp/bunya/iyakuhin/other/dl/090109-1a.pdf [Accessed 2009 Jul 15]
34. Murakami H, Handa H, Imai K, et al. Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan myeloma study group. Jpn J Clin Hematol 2004; 45: 468-472
35. Uhl K, Cox E, Rogan R, et al. Thalidomide use in the US: experience with pregnancy testing in the S.T.E.P.S. program. Drug Saf 2006; 29: 321-329
36. US FDA. Guidance for industry development and use of risk minimization action plans [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/ 05/briefing/2005-4136b1-03-Risk%20Minimization%20Action%20Plans.pdf [Accessed 2009 Jul 15]
37. US FDA. A synopsis of the elements of the S.T.E.P.S. program [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/04/briefing/4017B1- 06b%20Overview%20STEPS%20Section%20C%20Tab%207.pdf [Accessed 2009 Jul 15]
38. Honein MA, Lindstrom JA, Kweder SL. Can we ensure the safe use of known human teratogens? The iPLEDGE test case. Drug Saf 2007; 30: 5-15